UnknownPhase 2

The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter

Israel25 participantsStarted 2015-10

Plain-language summary

In this study we will explore the combined effect of Brimonidine and Timolol 0.5% (Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and a miotic effect on the pupil, however the combined effect of alpha agonist and beta blocker has not been studied.

Who can participate

Age range18 Years – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy adults subjects with no ocular pathology * Non pregnant women * Normal pupil response Exclusion Criteria: * Chronic topical treatment * Systemic medication affecting autonomic nerve system * History of intra-ocular surgery * Irregular pupil * History of ocular neurological or severe cardio-vascular disease

What they're measuring

Pupil diameter

Timeframe: two weeks

Trial details

NCT IDNCT02214680

SponsorCarmel Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-08

Contact for this trial

Orna Geyer, Professor

97248250926 orna_geyer@clalit.org.il

View on ClinicalTrials.gov More Healthy trials